{
  "doc_id": "Hepatocellulair_carcinoom",
  "created_date": "2012",
  "country": "NL",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "established established © 2012 - Amsterdam. Amsterdam.",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "table of contents",
      "text": "ablation ablation (Nonsurgical) radioembolisation radioembolisation (TARE) nSociety nSociety n",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "Hepatocellular Hepatocellular Carcinoma",
      "text": "this this guideline?. Dutch Dutch patients;carcinoma carcinoma (HCC). Health Health Care-to to order: guideline guideline intended? __MDTM_ __MDTM_ an",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "Surveillance",
      "text": "mPAGE-B mPAGE-B score: Age (Albumin Albumin years) (x109/L) (g/dL) <0 0 >/=250 0 >=condition condition and/Ultrasound Ultrasound [Support] <=1 mg/kg/Park Park (2020) and Park (2021) Kim Kim (17), park park (2020), and Park/2021) follow follow up). specificity specificity (Sutherland, 2017). patients patients (Kim, 2016; Park, 2020; Parks, 2021). echo echo ± B B (antiviral antiviral therapy) of of error- Cost Cost (meaning) gained gained (Life Life Year). of of 3% of of €recommendation recommendation 2: all all stages: MRI____MEDTM0_shortened MRI____MEDTM0_shortened protocol/without contrast). patient patient (Western Western setting), MRI MRI (long-term long-term analysis) stage stage (BCLC-0 or BCLC-A), __MEDTERM0_echography __MEDTERM0_echography (in in combination;_MENTERM0__ alpha fetoprotein) a a curative-combination combination ____MEPTERM0> alfafoetoprotein (AFP)-GRADE GRADE Sources: (Kim, 2016) Recurrence-free survival - of of comparator'three three month'rate rate (dynamic dynamic CT- level level (Hydney's disease) following following criteria: 1) parenchyma, parenchyma, 2) halo, halo, 3) Mosaic pattern, 4) scan, scan, biopsychiatrist'56 56 %, in in 29% in in 11%. cirrhosis cirrhosis (Child-Pugh A) be be 3% system system (US US $be be 3% 2. 2.5%. Nahon Nahon (2022) in in euro'Tan Tan (2021) of of (very) 198 198 % Km. Km. SPALATE: MRI MRI (value value KIM) Year Year (QALY) and Incremental $AL $AL-Effectiveness Ratio (ICER) (Kim, 2019; Lima, 2019 ; Tan, 2021). Life Life (HRQoL) is computed (Whitehead, 2010). Nahon Nahon (2022) 3% €7.744/LY €17/LY €15,477/LYG 2% €7.83/LY €7.487/LY €23.338/LYG 1% €7.942/LY €47.194/LYG ICER: Incremental Cost-EffectIVEness ratio; $2: Euro; LY: limitations limitations (-1; and and timing) the the Netherlands). following following questions: Imaging Imaging (MRI) ultrasound ultrasound (US) training training ( I I didn'excluded excluded (tab tab __MEDTERM11_ds), accuracy. accuracy.",
      "start_page": 4,
      "end_page": 18
    },
    {
      "heading": "The 'Diagnosis' Module isa",
      "text": "assessed assessed : Last authorized : b b modules: following following questions?",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "resonance resonance imaging",
      "text": "of of HCC? point point (e. claustrophobia), and and MRI;____MED ____MED sterM0/ ort ort use: Prevalence: 50% CT MRI 5%CI: 315 (95%CI: 385 (95%% CI: 35 (95% CI: 65 (95% procent procent procent: NCI, 9%: (95% C/ 25, 25, C/ 217, 2008 (95% C; C/ Luxemburg, 95% CI: Co/ / A, (95% and and / / / 1/ 00/ 125 25°C. (95% C < NA/ *contrast contrast (Chen, 2022) and and collaterality- cancer cancer (Radiology, Radiology, 2018). for for CT/carcinoma carcinoma (According to MRI) Cost Cost (mean seizure) the the cost(effectiveness) of of supinator'imaging imaging ~Conclusions Conclusions / Summ Sources: (Chen, 2022) - follow-up follow-up (6 6 months=reported reported head-construct construct 2-by-2 tables. ( Li (2019) of of Gd-EOB-the the patient'MEDLINE MEDLINE (inclusive Medline In-Process& Other Non-Indexed Citations), 60 60 (95%CI: 67, 67, I2: 62.43%) 69 69 (95% CI: 76, 76, I2: 74.74%) equals equals 2cm; 79 79 995%CI: 0.86, I2: 70.44%) Roberts Roberts (2018) CT CT (0.87, 95%CI: 94, 94, I2: 84.84%) agents agents (0.86, 95% CI: 95, 95, I2: 90.04%). CT CT (95% CI: Li Li (2019) 46 46 (95%CI: 0. 0.11) 79 79 (0. 0.07) 98 98 (95%CI: 00, 00, I2: 13.3%) 96 96 (95%CI): 99, 99, I2: 0%) Li Li (2019) of of CT: limitations limitations (of of bias: domain domain (sample sample sizes)); conflicting results (inconsistency inconsistency publicized: limitations limitations (of of bias: Roberts (2018)judged 5/and and 4/and and timing; Li (2019) judge 2/limitations limitations (of of bias: Roberts (2018) judge 5/and and 4/and and timing; Li (2019)judged 2/and and 2/index index test; questioning questioning question: CT-scan CT-scan (scan scan protocol) imaging imaging (protocol protocol ) with patient'following following criteria: to to head-were were 1) or or 2) CT findings (with with cirrhosis), or 3) six six months' practice practice eidelins: hepatology_Jul hepatology_Jul 1;69(1):imaging imaging , hepatocellular hepatocellular carcinoma: biopulate biopulate [the the applicant'at at biopt: growth growth stated; recommended recommended (representativeness representativeness problem), is is identifiable; present present (to to tumor) or separate bioptally; unequivocal unequivocal (WHO 5) present present (focus focus > trabecular trabecular thickness) or progenitor'tumor tumor <= 2 cm __MEDTERM0_/the the seeker'tumor tumor >= tumor tumor > tumors tumors (lesions lesions > measures measures non) tumors tumors =lesion lesion >T4 T4 Tumor(s) /portal portal vein/vena hepatica and/Disease Disease (AASLD) (Marrero, 2018), Liver Liver (EASL) the the patient'Oncology Oncology (ESMO) (Vogel, 2018) EASL-Dose EASL-Dose (error error (EASL, 2018). interest interest (EASI, 2018) in in 60% AASDL AASDL (Marrero, 2018) and and metastasis/erroglobin, erroglobin, 2018). AASLD, AASLD, 2018), liver liver biobiologist'biopsy biopsy (and and metastases) ESMO ESMO (Vogel, 2018). the the literature; __MEDTERM0_ __MEDTERM0_ cirrhosis: consultation consultation (MDO). __MEDTERM0_ __MEDTERM0_ cirrhosis: literature literature ́s analysis point-test test (gold standard ́) follow-up follow-up and/PALGA PALGA (Pathological-Anatomical Nationalized Archive), stage stage (TNM8). resection resection plane(ks), oncral oncral margin= dedifferentiation dedifferentiation (Burt, 2020; WHO, 2019; differentiates differentiates 8/Mauro, 2022). morphological morphological and/Glypican3 Glypican3 (GPC3), 70 70 (HSP70) synthetase synthetase (GS), 2019 2019 (Marrero, 2018)- guideline 2018 (EASL, 2018). Conclusions Conclusions / select select (__MEDTERM6_hods) Medline Medline (via OVID) review review (via Embase.com) following following criteria: carcinoma carcinoma (patient'the the patient'Cancer Cancer Reporting; Sydney, Australia. TSI: 978-1-922324-09- 2019 2019 Sep;71(3):HCC HCC (relative to >2cm) score score (to to F0- 3) (Lin, 2016), to to (very) value value (Lins, 2016);Lin Lin (22) the the patient'carcinomas carcinomas (>2 centi_MEDTERM0_er) smaller smaller (2-centi_MENTERM 2-centi_MENTERM 0_er). consultation consultation (MDO) a a HCC'a a non- GRADE GRADE Sources: (Kim, 2011; Lin, 2016) GRADE GRADE Sources: (Fischer, 2015); negative negative (n=44SE), positive (n=0), agent agent (n=3), was was n=47 (negative), n=4 (positive), and n= 4 (unclear). 3 3 (IQR : 4. 4.0) 5 5 (7. 7.4) 1, 1, Ts-Ts-S-N-with with AFP>200ng/and and didn'Lin Lin (22) chaffer. chaffer. (F0 F0 (n=21), F1 (n=18), F2 and=2), F3 (n =14), or F4 (n=90, cirrhosis). medium medium (Gd-DTPA, 0.2mg/kg, 1.6- 1.8ml/sec) T2WIN. T2WIN.",
      "start_page": 22,
      "end_page": 52
    },
    {
      "heading": "98, 98, n=21).",
      "text": "Lin (22) detection detection HCC's (1-2cm respectively) from from ?? Lin Lin (21). PPV PPV (95%CI) F0 F0 100% (91. 91.7% (0.62 -T2-intensity T2-intensity (not isointense): 0.50 (95%CI: 0.36-0.64). Central enhancement (no): 0.73 (95%CI : 0.59-0.84). Satellite lesions (yes): 0.96 (95% CI: 0.87-1.00). The 95%lesions lesions (yes): 0.54 (95%CI: 0.43-0.65). Lin (22) is is F0-(C)-(A)- limitations limitations (of of bias: Nadarevic (2021, 2022) reference reference standard); patients patients (for for imprecision: confoundance confoundance intervals); limitations limitations (of of bias: events events (carrying about 50% ground ground floor) of of bias: studies studies (carrying about 50% Nadarevic Nadarevic (2022); follow-up follow-up patients' opinions (of of life) following following criteria: carcinoma, carcinoma, patient'we we didn'literature literature (Fischer, 2015; Kim, 2011; Lin, 2016). cm. cm. ? condition condition (liver liver cirrhosis) tumor tumor contiguousness? intervention intervention (patients patients (their their caregivers) assessing assessing patients' the the patient'interest interest (be be present). of of recommendation: GRADE GRADE Source: - on on - overtreating wepatients- and externate. # 75 75 (95%0. 0.78). of of 3- following following question: carcinoma carcinoma (HCC) undergoing undergoing hepatectomy? P:model model (internally internally (e.g., cross cross validation) bias bias and/so so (to to diarrhea). assessed assessed : 01-authorized authorized : abducted abducted (Administered) Cephalometrically-Captained Cephalometrically-Captained Drop-Drop/Patient'complications complications (≥ grade III) process process (Ding, 2022). a a (direct) choice choice (join decision). to to discuss: the the (relative) role role (resection resection costs). of of abstinence: Conclusions Conclusions / Outcome Outcome 1- complication complication (≥grade III) equal equal (extremely) major major portal/complications complications (Clavien- Dindo grade 3+) significant significant (p=0.574). Publication Publication bias: published published (yet). Post-operative complications: inconsistency inconsistency (different different ways). following following question: survey survey (lap lap orthopaedic) ( old old (>10 years ago) recent recent developer'Patars Patars ago) assessed assessed : 01-authorized authorized :hepatocellular hepatocellular carcinoma: 2022 2022 Jan;11(1) Anselfli:Milan Milan Criteria: Apr Apr 1;273(4):656-666. doi:.1097/SLA.004350. PMID: tolerability. tolerability.",
      "start_page": 53,
      "end_page": 74
    },
    {
      "heading": "Radioembolization",
      "text": "patients patients (BCLC A, n=27; BCLC B, n=68; BCL C, n=114) in in 62% the the TMC'yttrium-90 yttrium-90 (90Y)-enrolled enrolled 41/of of >size size of>stages stages (without PVT) TARE TARE 2+cm cm (Salem, 2021). of of TES- patients patients (their their caregivers) Cost Cost (meaning seizure) in in >Sharing Sharing ́patients patients __MEDTERM296_<tumors tumors <5 cm (the Baere, 2022). needed needed (cost-effectiveness), GRADE GRADE Sources: (Kolligs, 2015; Pitton, 2015 ; Salem, 2016 ; Dhondt, 2022) radioembolization radioembolization (TARE) chemoembrolization chemoembrolization (TACE) GRADE GRADE Sources: (Comligligations, 2015 ?? Pitton Pitton (2015) than than 50% 34 34 mmol/44 44 mmol/ group group (IQR IQR 63-72; 87% male) Dhondt Dhondt (2022) was was 94% and and 100% was was 88% versus versus 87% group. group. # 6. 6.0% and 1.0% 20. 20.5%, PitTON PitTON (2015) in in median-cm24(24-24) equal-m24 equal-m24 (24.22) __MEDTERM451_ __MEDTERM451_ (TARE TARE group) progression progression (TTP). Salem (22) group group (>26 months old). months months (HR 0.122; 95% 0. 0.557). limitations limitations (risk of bias), -low-level low-level confidence-syndrome syndrome (patient patient assessment) (see RoB assessment), indirect consciousness (-1; control control group) patients patients (imprecision, -1). following following question: radioembolization radioembolization (TARE) chemoembolism chemoembolism (TACE) stage stage 0-B?stage stage 0-B; I: Radioembolization (transarterial radioemulization tartrate) Progression-free survival: Absolute difference >5% difference difference >3% Ratio Ratio (HR) Complications aside: Late differences >3% or or >10% from from 01-01-2000 until 08-Medline Medline (via OVID) and Embase (via Embase.com) from from 01-between between 02-and and ablation? abulation abulation (6 6 weeks) treatment treatment __MDERM296; transarterial radioembolization ( patient patient population;and and performed;RFA RFA (large) ___ ___ 39% the the Recommendation: GRADE GRADE Sources: (Liu, 2011; Morimoto, 2010; Peng, 2012;Peng, 2013; Zaitoun review, 2021; GRADE GRADE Sources: (Peng , 2012 ; PenG, 2013 ; spleen spleen . group group (52. 52.1±14.5; 88% male) group group (51. 51.9±13.6; 83% male). groups groups : RFA RFA (n=20), other. other. (n=10) and MWA (n=10) group group (nt=20). concealment concealment __MEDTERM296brengt'time-points time-points (1-, 2-, 5-, and 7-year) ratio ratio ( of of 6% of of 39% is is 33%, limitations limitations (bias, bias, -1 (see RoB assessment)), indirectness gained (-1; control control group) patients patients (imprecision, -1) levels levels ( Local tumor control: progression progression (complete response + partial response + stable disease). Complications: treatment treatment (or or serious/major adverse events). clinically clinically (patient) difference: Overall survival: Absolute difference >5% difference difference >3% ratio ratio (RR)- <=imageguidance imageguidance - Dec Dec 5;6:1-8-. doi: 10.1016/Erratum Erratum in: Dec Dec 17;8:100308. PMID: 30547062; PMCID: S. S. doi: 10.1002/29. 29. PMID: ABLATION ABLATION alone: systemic systemic therapy? measure measure (imprecision), carcinoma carcinoma (HCC) study study ( deelnemersn, 2020). Cost Cost (mean seizure) ratio ratio (ICUR) Conclusions Conclusions / Overvival Overvival (crucial) TARE TARE (using using BSA-_MEDTERM296_hod) zidovudine zidovudine ( The mean (SD) 5 5 (12.9) 7 7 (10.6)group group 147/182 (80.8%) SIRT_78 SIRT_78 (84.8%) Eligible Eligible patient'were were included: survival survival (___MEDTERM451_) (Crucial) Two studies (Chow, 2018; Vilgrain, 2017) survival survival (events events (AE) (important) Two studies (Chow, 2018; Vilgrain, 2017) Chow Chow (2018) to to ?? 5 5 (n=21) 1 1 (nt=22) effect effect (p = 0.006), effect effect (P < 0.0001) observed observed (p=0.12). as as follows: rate rate (___MEDTERM444_) absence-free absence-free stay-of-life ratio. {\\pos(192,210)} following following criteria: surgical surgical intervention; comparered systemic therapy; of of interest; review review (SR) (controlled controlled trials; RCTs), or RCT; K. K., Raj, A., S. S., Cua, I., R. R., Teh, C ., H. H., W. W., Group Group (2018). __MEDTERM1_: H. H., Bouattour, M., M M ., Assenat, E., Gregory, J., P. P., Chatellier, G., Vilgrain, V., Group Group (2021). Hepatocellular Hepatocellular Carcinoma: 2017 2017 Mar;20(3):336-344. doi: 10.1016/4. 4. PMID: the the patient'is is __MENTERM296______~/QQ]-2rd-graded 2rd-graded B/Q-B/1st-line 1st-line B/H/SQ-T-D-I-G/L- ___ ___ MED_Dser_M^dser/M^Dser-Dser/Two-Der-Dr_Dr-Dst/Gr/Dr/Corpor-Drr/Lye-DR-Dsl/Sp/ Conclusions Conclusions / Conclusions Conclusions /survival survival (crucial) with with ? GRADE Sources: (Cheng, 2022) hepatocellular hepatocellular carcinoma: the Kudo, 2018) events events (important) ____ GRADE Sources: (Bruix, 2017) rate rate (important) were were treatment-naïve; or or placebo; outcome outcome reports: __MEDTERM44; Year Year Trial/1988 1988 -/III 1999 -/II 2005 - and/Atezolizum Atezolizum (Finn, 2020) (6. 6.1). __MEDTERM0_treatment __MEDTERM0_treatment (Brien, 2017) • mean mean (SD) 9 9 (11.2) 3 3 (10.2)group group 260/299 (87%) were were revealed: atezolizumab atezolizumab (21-day 21-day cycle) plus __ gewetenM6_(IV, 15 mg/cycle cycle (n=336), me. me. (21-DAY 21-DAY cycle) (n=165). intervening intervening 137/46 patient'with with (unresectable) HCC? Bruix Bruix (2017) - countries countries (152 sites) and and Australia;69 69 (95% 0. 0.87). 92 92 (95% 1. 1.06) is is not; __MEDTERM296_ __MEDTERM296_ (imprecision, -2). progression-free progression-free survival' median median [ME] limitations limitations (bias, bias, -1 (see RoB assessment)) events events (imprecision, -2). __MEDTERM296_ __MEDTERM296_ (imprecision, -2). outcome outcome ́events events (important) group, group, 76/329 (23.1%) a a treatment- with with 25/156 (16.0%) Atezolizumab Atezolizumab +__MEDTERM296_ __MEDTERM296_ (imprecision, -2). of of life's territory' survival survival (___MEDM444_) (crucial) Bruix Bruix (2017) was was 40/379 (10.6%) to to 8/194 (4.1%) 6. 6.4% (95% 10. 10.6). RCT. RCT. #__MEDTERM296_ __MEDTERM296_ (imprecision, -2). of of life's granted ratio; following following question: with with (unrecognized) synthesized synthesized (by by __MEDTERM296_a-analysis) select select (_ The second- Netherlands Netherlands are: __",
      "start_page": 75,
      "end_page": 135
    },
    {
      "heading": "References",
      "text": "2019 2019 Apr;120(9):896-902. doi: 10.1038/s41416-4. 4. PMID: 30944458; PMCID: Bronowicki Bronowicki JPijkr",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "the the follow-up",
      "text": "assessed assessed : Last authorized : table table modules: you you answer",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "first first year",
      "text": "hepatocellular hepatocellular carcinoma? and and family/a a (validated) appetite, appetite, nausea/loss loss (Sun, 2008). diseases diseases (Demark-Wahnefried, 2006). guideline guideline 'and and 2006; 24(32): substance-based. substance-based. 2007; NVD. NVD. Guideline: Nurs. Nurs. 2008; Oct 12(5) {months] {",
      "start_page": 141,
      "end_page": 143
    },
    {
      "heading": "cancer cancer manifestations",
      "text": "follow-up follow-up schedule: determine determine CT/ life life (alpha-FoetoProtein alpha-FoetoProtein (AFP) the the recommendation: __MEDTERM0_ __MEDTERM0_ (consideration on) arise. arise. Patient'of of HCC'screening screening options: May May 21;8:106. doi: 10.1186/1472-6963-106. PMID: 18492286; PMCID: WSL, WSL, Tel:",
      "start_page": 144,
      "end_page": 146
    },
    {
      "heading": "module module isa",
      "text": "reviewed reviewed : Last authorized Intervention: database. database. • Patient'the the patient's request • Medical consultation • Internal physician's participation • present present • Radiologist's discretion • Not available • abnormality abnormality • Receiving advice • Physician's recommendation • examination examination • basis basis • Please follow-up • room room • confirmed confirmed risk/ Plan Plan (RMP) Agreement Agreement (WGBO) of of follow- TEAMS. TEAMS. Recommendation-1: consultation consultation (MDO). the the physician'dvies dvies guidelines/files/the the SONCOS",
      "start_page": 147,
      "end_page": 151
    },
    {
      "heading": "Organizational Treatment Phase",
      "text": "a a patient;hepatocellular hepatocellular carcinoma? the the benefit/ advice advice (the the risk/ the the benefit/ path. path.",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "Recommendation-1: Organizational Treatment Phase",
      "text": "Rationale of recommendation: the the Patient'assessed assessed : 01-review review : 0-Lifestyle Lifestyle contraindications- be be chosen: radiotherapist-oncologist radiotherapist-oncologist (nurse nurse practitioner) assessed assessed : 01-authorised authorised : 01/Database. Database.",
      "start_page": 152,
      "end_page": 155
    },
    {
      "heading": "headed headed <none>",
      "text": "Row 1: Row 2: Row Row 3: Row 4: Gastrointestinal-Liverartsen Gastrointestinal-Liverartsen © 2012 - Medical Medical Specialists",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "headed headed <none>",
      "text": "Row 1: © 2012 - Medical Medical Specialists",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "headed headed <none> (column 1)",
      "text": "Row 1: Row 2: Hepat Row 3: row 4: established established © 2012 - Row Row 5: a a Pro",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "headed headed <none> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: tocel Row 5: Row 6: Row 7: Row Row 8: oduct unders",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "headed headed <none> (column 3)",
      "text": "Row 1: row 2: Row 3: Row 4: rlular carow 5: Row 6: ~Row 7: Verrow Verrow 8: the the 'Kennisi",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "headed headed <none> (column 4)",
      "text": "Row 1: Arcinoma Row 2: Row 3: Road Road 4: Medical Medical Specialists",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "heading heading <Hepatocellular Hepatocellular carcinoma>",
      "text": "as as follows: to to order: follow follow up: ROW ROW 6",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <Hepatocellular Hepatocellular carcinoma>",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025 3/155",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <Surveilance>",
      "text": "ROW 1: ROW ROW 2: Surveillance Row 3: Row 4: • Raw Raw 6: patients patients • hepatocellular hepatocellular carcinoma? • Raw 7 •raw 8: 9 9 : Row 10 • 11 11 • patient patient • EU/ 1/ 97/ risk risk ≤risk risk ≥HCC. HCC.' Row 28: Row 29: mPAGE-B Score:' Row 30: ~ Row 31: on on 13-05-2025 4/155 Row 32:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: ROW 3: Row Row 4: Age (as as follows: CARTON OF ROW-2 2 - MRI MRI (standard standard protocol) Park Park (2020) and Park (2021) Kim Kim (22), park park (2020), and Park (2021) include: Ro2N Ro2N = also also indicates:",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: Row 5: Row Row 6: Row 7: reported reported (Kim, 2016). patients patients (Kim, 2016; Park, 2020; park, 2021). cirrhosis cirrhosis (Van Meer, 2015). Row 18: Row 19: search. search. However",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: Hepatocellular carcinoma'Row 5: sensitivity to 97%, lower lower specificity) of of 45% stage stage (for for example;to to 63%, lower lower acuity) (Tzardceva, 2018). incidence incidence (Curran, 2023). occurrence occurrence <1.5% include: 1) causes causes (Chiari Chiari syndrome); 2) Biliary atresia/Kasai Kasai operation; 3) antitrypsin antitrypsin deficiency: of of Wilson'surveillance surveillance (Patmore 2023). Row 10: waived waived (Patmore 20233). Road 11: Row 12: patients patients (their their caregivers) Road 13: reduced reduced by",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Associated 'chance'",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "A row 1: Row 2: row 3: row 4: row row 5: the risk/ surveillance surveillance (from Meer, 2016). made made (Shared decision making). causes causes (Chiari Chiari syndrome), biliary biliary atresia/diseases diseases (type type 1) on on HCC'Row Row 18: Row 19: on on 13-05-2025 8/155",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Undergoing Row 4: Road 5: Background Row 6: Raw 7: Carcinoma Carcinoma (HCC) malignancy malignancy . survival survival ; Singer'imaging imaging (MRI) Row Row 10: Row 11: Conclusions / ROW ROW 12: ́ Row 13: Sensitivity Raw 14: ~ Row Row 15: hypophosphatasia. hypophosphatasia.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: row 3: row 4: row row 5: 7 7 : {8 8 ources: (Kim, 2016; Park, 2021; Sutherland, 2017) Raw 9: • Row-r achtergrond",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: ultrasound ultrasound (US) and gadogetic acid- acid acid (Primovist®) initiator. initiator.",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: dynamic dynamic CT- scan. Row 7: Row 8: old old (Royal Clinic disease) .",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: 2 2 (after after surgery)",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: MRI MRI (CMRI) imaging imaging (AMR) acid acid (Primovist®) Gadoxetic Gadoxetic acid(Prim",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Row 6: Park Park (2020). Row 7: Row 8: Park (2021) Park Park (2021) reported (very) Row Row 9: Row 10: Sutherland (2017)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: map. map. #Row 3: #Raw 4: # ultrasound. ultrasound. #clear. clear.",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: Lima (2019)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: on on 13-05-2025 12/155 Row 2: Row 3: Row 4:",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: cirrhosis cirrhosis (Child-Pugh A) be be 3% 1. 1.5%. 1. 1.5% .",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: Tan (2021",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: conductedRaw conductedRaw 2: handledRow handledRow 3: ROW 4: equal to all; ROW 5: of of (very) early-stage HCC (Table 1.1) Row 6: accuracy accuracy (Rov&) Rowwind is",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: row 2: row 3: row 4: row 4: row 5: rod rod 69% biedt biedt rate: Raw Raw 46% kg log X-ray: rowd 86% ́ Row Row 79% ́ POW 84% ́ mg mg ́ HCC HCC (all stages) Life Life (HRQoL) is combined (Whitehead, 2010). expression expression (life life year) 45. 45.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "headed headed <Surveilance> (column column 1)",
      "text": "Row 1: Hepatocellular carcinomaRow 2: Row Row 4: of of HCC(all stages)(Rov IX) expression expression (life life year) compared compared (Krummenauer, 2005) Row 34: Row 35: Row Row 36: 33AM 33AM ROWS",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "headed headed <Surveilance> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 3: Road 4: Row 5: Row Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row Row 25: Row 26: Row 27: Row 28: Row 29: Row 30: Row 31: slow 25:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "ROW 1: ROW 2: Row 3: row 4: Raw Raw 5: Row Row 6: Road 7:$20, Kim (2019)5%$10.191/QALY$10,163/QALI$107, QALJRow 8: ́4%$9,704/000-Q, 000-Q, Row/Q, ROW",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: Nahon Nahon (2022) Life Life Yearsheimer's disease (LY) Gained Gained (LYG) 4. 4.' Row 3: Row 4 : USICER USICER COPPEN/PORCHINE < 2x12.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: row 3: Row 4: Road 5: Hepatocellular carcinoma' Row 6: low. low.' ROW 7: ́Row 8: Specificity'than than 10: limitations limitations (-1; and and timing) GRADE. GRADE.'Row 22: Row 23: limitations limitations (-1; outcome outcome measures) safe safe (-1); this. this.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Veronica: Row 1: Row 2: Row 3: row 4: Hepatocellular carcinoma' Row 5: R: Disease Disease (AAASLD) criteria (Marrero, 2018) LIVER LIVER (SELVEL) Liver, Liver, 2018); Row 6: for for (very)diagnosis. diagnosis.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: Road 6: Medline Medline (via OVID) and Embase (via Embase.com) include include RCT's. Row 7: − Row 8: Row Row 21: Row 22: Responsible Row 23: - Row 24: Last assessed 01-01-2024 Row 25: Last authorized: 01-01/2024",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: References Row 4: row 5: criteria criteria 2018: Available Available from:'https://www.nvmo.org/over-de-advices/ Row 6: C",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: HCV HCV infection? 2021 2021 Dec;94:6- 14. Doi: 10-1016/23. 23. PMID: 34563447. Row 2: Row 3: 13-25. 13-25.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: K",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 19/155 Row 3:",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: v",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "headed headed <Surveilance> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 20/155",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "headed headed <Surveilance> (column column 1)",
      "text": "Row 1: Row Row 2: v",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "headed headed <Surveilance> (column column 1)",
      "text": "Row 1: Row 2: on on 13-05-2025",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "headed headed <Surveilance> (column column 2)",
      "text": "Row 1: Row 2: 16. 16. PMID: 2732036 row 3: on: Bull. Bull. 2010;96:5- . Row 4: Row 5:",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "headed headed <Surveilance> (column column 3)",
      "text": "Row 1: Row 2: Grandma: Row Row 3: -21. doi: Row 4: Row 5: 20/155",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "heading heading <The module 'Diagnosis' exists>",
      "text": "Row 1: Row Row 2: Diagnosis Row 3: Row 4: sub sub modules: Row 5: Row Row 6: Row Row 7: Row Row 8: Road 9: Responsible Row 10: ~ Row 11: Last assessed: Row 12: Last authorized:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <The module 'Diagnosis' exists>",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025 21/155",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <The module 'Diagnosis' exists> (column 1)",
      "text": "Row 1: Row Row 2: Diagnosis Row 3: Row 4: row row 5: row row 6: row row 7: row row 8: row 9: Responsible row 10:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <The module 'Diagnosis' exists> (column 1)",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <The module 'Diagnosis' exists> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <The module 'Diagnosis' exists> (column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: olgending Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: dence Row 13: Row 14:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "headed headed <The module 'Diagnosis' exists> (column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: table Row 13: Row 14:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <The module 'Diagnosis' exists> (column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: b modules: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <The module 'Diagnosis' exists> (column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: entire Row 13: Row 14:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <The module 'Diagnosis' exists> (column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "headed headed <The module 'Diagnosis' exists> (column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: row row 13: row 14:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "headed headed <The module 'Diagnosis' exists> (column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "headed headed <The module 'Diagnosis' exists> (column 10)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: produ Row 13: Row 14:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "headed headed <The module 'Diagnosis' exists> (column 11)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "headed headed <The module 'Diagnosis' exists> (column 12)",
      "text": "Row 1: Row 2: Row 3: Row 4: row 4: row 5: row 6: row 7: row 8: row 9: row 10: row 11: row 12: guess row 13: row 14:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <The module 'Diagnosis' exists> (column 13)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14: 21/155",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "headed headed <CT versus MRI>",
      "text": "Row 1: Row Row 2: Row Row 3: ROW 4: efficacy efficacy (5. 5.1). Roberts Roberts (2018) curve curve (the the curve) relatively relatively similar;_MEPTERM0_ CT-scans'. the the MRI-m^",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: row 3: row row 4: of of patients;Row Row 5: Road 6: of of n=Row Row 7: of of 30%, 50% and 70% opportunit opportunit 45% 20% 50% 70% 40% 39% 5% 25% 25° C. (95% A. A., C. J., D., V., F. C., L., E., M., B., Q., T., K., R., C, C, L",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "headed headed <CT versus MRI> (column column 1)",
      "text": "impairment impairment rod: CZ CZ 97/ examinations examinations (Chen, 2022; Li, 2019; rob row 9: Raw 10: from 30%, 50% and 50% Row Row ribavirin",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "headed headed <CT versus MRI> (column column 2)",
      "text": "Row 1: Row 2: Row Row 3: row 4: of of n= 10 row 5: ROW 6: 8 8 8: berts, 2018) (95%%: cytotoxic cytotoxic 9: Raw Raw 10: ORT used. Prevalence: 50% Rov 12: ́ 465 465 45% C-value:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "headed headed <CT versus MRI> (column column 3)",
      "text": "Row 1: Row 2: Row Row 3: row 4: row row 5: Row Row 6: Prevalence: 70% Row 7: ́ 8 8 (95%: ~ 57 Row 9: % CI: 0) 4 ader (95% CI: 392-483) 539 (95%CI: 490-588) Rov 11: CI: 21 (95% C. I.: 15-45) 18 (95% CI;",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: ROW 3: Road 4: Raw Raw 5: 644 644 (95% CI: 9 9 - 47 47 [95% CI: 95% confidence confidence rating] 49 49 (Roy 45) (95% C-58 45, 95% confidence rating) (95% Liver Liver (EASL) the the RBC",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: for ct/ carcinoma carcinoma (Radiology, Radiology, 2018; Elmohr, 2021). The CT/ to to non- 10 10 : Cost (meanload) Row 11 : cost cost (effectiveness) MRI MRI . Row 12 : 14 14 : risk risk of",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "ROW 1: ROW ROW 2: Row 3: Convulsion Row 4: Row 5: Background Rrow 6: Road 7: recurr recurr (see above). at at ~ 1/ Row Row 20: Low Row 21: {PRADE ROW 22: }Row 23: ́Row 24: −syndrome syndrome Rovalex(Sources) lung. lung. −Row 24:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: row 2: row 3: row 4: row row 5: CT. CT.' Row 24: ROW ROW 25: Row 26: ́ Row 27: ~Sources: (Li, 2019) Row 28: − Row 29: -echocardiography echocardiography (ROVED-RAD-ROXAL-ROVAL-RAVAL-NOVAL",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: CT-scan CT-scan (16, 64, and/6-5mm 6-5mm (2 2 studies) and MRI (and and /5 5 (4 4 studies), dimeglumine dimeglumine (=1)/=2c/diglutinamide ( MRI MRI (instead of both), used used CT=thert) beam beam (and and four) imaging imaging (and and six) and and nine) Row Row 11: on on 13-05-2025 28/155 row 12: Row 13: Row 14:",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Road 4: row 5: Raw Raw 6:years years (three three studies), 254 254 (one one study). • syndrome syndrome (respiratory distress syndrome) • syndrome syndrome (CT CT (95%CI: 62, 62, I2: 52%) MRI MRI (95% CI: 81, 81, I2: 94.6%). 64 64 (95%ci: 70, 70, I2: 61.79%) 70 70 (95%C: on on .88 88 (95%CI: 92, 92, I2: 90.89%) 87 87 (95% CI: 91, 91, I2: 92.1%) centimetres centimetres (3 studies), CT CT (95%Cl: 97, 97, I2: ROW-",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: AUC Row 2: Row 3: row 4: ROW ROW 5: Rov 6: Raw Raw 7: and and 8°C (Rov-I-QOL): curve curve (AUC-I) Roxet 13: Chen (2022) 17 17 (00 00 (95%CI: 0. 0.52) 82 82 (95%CI :0. 0.93) 002 002 (95%CI): 0.84 (95%CI) 84 84 (95%CI; 0. 0.95) Row Row 23: Rov 24: Roberts (2018) syndrome. syndrome.",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Road 3: row 4: Raw Raw 5: Roberts (2018) 96 96 (95%CI: 97, 97, I2: 80.31%) 94 94 (95% CI: 95, 95, I2: 60.07%) 98 98 (95%Cl: 00, 00, I2: 82 82 (95%CI: 0. 0.85) 0. 0.9095%CI: MRI. MRI.' Row 15: Row 16: Costs Row 17: consciousness consciousness (than than death) (Rovical disease syndrome)",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Veronica: Row 1: Row 2: Row 3: row 4: ROW ROW 5: limitations limitations (of of biases; domain domain (sample sample faces)); Li Li (2019) performed the Deek'publication publication bias).' Row 11: Row 12: limitations limitations (of of bias: Roberts (2018)judged 5/and and 4/syndrome. syndrome. 3/and and 2/and and timing); publication bias (publication publication bias: Li (2019) performed the Deek'publishing publishing bias).' Row 16: Row 17: ~ Row 18: on on 13-05-2025 32/155 Row 19:",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Road 3: row 4: row row 5: row row 6: Row 7: raw raw 8: following following explanation:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: O:costs. costs.'Row 2: Row 3: Relevant measures' Row 4: decision decision making; tables. tables.' Row 13: Row 14: Responsible Row 15: ? Row 16: Previously assessed 01-01-2024 Row 17:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: row 3: row row 4: Last approved : 01-01-2024",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 4: A",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 34/155",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: Row 4: Row Row 5: row 6: liver liver cirrhosis? Road 7: − Row 8: Recommendation Row 9: ● Row 10: Recommendation-1 Row 11: a a ≥ a a ≥ 1 mg/ area area (5. 5.1). vascular vascular cirrhosis/ Use Use (CHMP) CHMP. CHMP. The",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: ROW 3: Row Row 4: standard standard report; Module Module (PPM): Role 5: Road 6: where where applicable: Raw 7: size size (the the vial) distance distance >if if possible) staging staging (of of fibrosis) Row Row 22: Row 23: be be demonstrated: Row 24: no no (vital) biopsy biopsy (after extensive/relevant relevant area), Row Row 25: on on 13-05-2025 36/155 Row 26:",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row Row 2: differentiation (advice; WHO WHO 2019); Row 3: status resection margin; Row 4: vaso-invasive vaso-invasive growth; row 5: capsular capsular bursitis; Road 6: if if present; row 7: unequivocal unequivocal (WHO 5th ed) if if present",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: representativeness problem), is is identifiable; Row 2: present present (cave",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: to to tumor) separately separately bioped; Row 2: unequivocal unequivocal (WHO 5) present present (to",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "ROW 1: ROW 2: Row 3: row 4: Row Row 5: (hairy-form hairy-form rejection) ~ Row 6: Road 7: Dow Dow 8: tumor tumor <= 2 cm _MEDRM0_/tumor tumor > invasion invasion ~ Tww/dummy ~Row Roberts (2018) reference reference (gold standard) Clinical follow-up and/ the the Community",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: Row 5: carcinoma carcinoma (and and LR-4) of of (at least) results results ('sampling error') nodi nodi <a a biopt(s) the the patient'interest interest (EASL, 2018). in in 60% cm cm (Forner, 2008). carcinoma carcinoma (AVEL, 2018) .Row 6: Row 7: AASLD AASLD (Marrero, 2018), patients patients __",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "ESMO ESMO (Medical Medical Oncology; Vogel, 2018) imaging imaging modality;the the benefit/ be be found",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: assay assay (gold standard')",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 2: Road 3: Row Row 4: Raw 5: efficacy efficacy (4. 4.4). Torbenson Torbenson (2019) in in patients;_MEDTERM0_ cirrhosis: RowTerma RowTerma ́relevant relevant and/ Use Use (CHMP), time time as",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Row 3: ROW ROW 4: row 5: For consultation/ panel panel (Pathology Pathology Panel; dlpp.nl) raw raw 7: Row Row 8: reports reports (Sluijter, 2016). the the >2 cm distance) out out (liver liver disease). ́Row 15: Row 16: In a (pre-)and and (early) HCC ́ ROW 18: is is < a a leukokeratosis",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "ROW 1: ROW 2: Row 3: row 4: row row 5: component component (EASL, 2018; WHO, 2019; Montiri, 2022; Ziol, 2018); Calderaro parallelle19,; Nault, 2013; Villanueva, 2011; Miltiadous, 2015). ́ ROW 6: ROW 7: tumors tumors ́prognosis prognosis (EASL, 2018). ROW 13: Row 14: examination examination ~_",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: row 3: row 4: row row 5: principle principle less/non-cirrhosis non-cirrhosis (adenoma adenoma (HCA), hypervascular __MEDTERM0_astases etc). Row Row 7: follow-up follow-up and/ 9 9 : Conclusions /10 10 :",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: O:value value , curve. curve.' Row 2: Row 3: Row Row 4: ROW 5: on on 13-05-2025 43/155Raw 6:",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: hepatocellular hepatocellular carcinoma(HCC) decision decision making; theius theius 6: Row 7: you. you.",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 5: B",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Hepatol Hepatol 2016;65:Row Row 2: E",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: on on 13-05-2025 44/155 Row 2: Row 3:",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: Row 5: Practice Practice Guidelines: 2018 2018 Jul;69(1):182- 236. doi: 10,1016/Eramum Eramum in: 2019 2019 Apr;70(4):817. PMID: 29628281. Row 6:",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 45/155 Row 3:",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: 23;13:1019638. Row 6: W",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 46/155",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "headed headed <CT versus MRI> (column column 1)",
      "text": "Row 1: Row 2: Row Row 3: 23;13:1019638. Row 4: W",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "headed headed <CT versus MRI> (column column 1)",
      "text": "Row 1: Row 2: on on 13-05-2025",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "headed headed <CT versus MRI> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: O, O, Ganne- atocellular carcinoma: Row Row 6: Row 7: 46/155",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row scan 1: Row Row 2: Row Row 3: Row 4: Row Row 5: Row 6: imaging imaging (or or CT) liver liver cirrhosis? Row 8: Recommendation Row 10: value value (Lin, 2016). carcinomas carcinomas (2 2 centi_MENTERM0_er) 0. 0.9*S. <=1 mg/kg/kg]. ==49.",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: Lin Lin (15) carcinomas carcinomas (>2 centi_MEDTERM0_er) smaller smaller (1 ); centi/ presentation presentation (MRP",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 2: row 3: row row 4: experience experience EU/ 1/ 036/ Row Row 11: Row 12: Conclusions / Row Row 13: ́ Row 14: ROW ROW 15: ~over over me/2 2 Rowter-Cr(S) Rovver Rovver-C",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Road 3: row 4: Row Row 5: Row Row 6: Low Row 7: •Row disease; row disease; cow disease; developmental disease; respiratory disease; systemic systemic disease; chronic lymphocytic leukaemia; distress distress syndrome; heart heart disease; clinical trials; heart heart failure; therapy. therapy.",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: Row 5: Fischer (2015) cirrhosis. cirrhosis. Patient'he he didn'Row Row 6: Row 7: Kim staart) center center (Center, Center, Korea). excluded excluded (n=68), hypervascularity hypervascularity (area >70%), three three groups: cirrhosis cirrhosis (n=107), cirrhosis cirrhosis [antigen antigen and/or anti-HCV, n=62), 10 10 (n =127), cirrhosis cirrhosis (antigen antigen &/hepatitis hepatitis (n=22), and",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "headed headed <CT versus MRI> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: Road 5: Hepatocellular carcinoma' ROW 6: B B (n=56), hepat hepat C(n=C C (n=1). patients patients (n=21 males, n=16 femals) years years (range: 23 to 81) disease. disease. • neck. neck. patient'MRI MRI (n=142 males, n=62 females) years years (SD: 12.49) HCCs HCCs (1-2cm and >2cm respectively) with CT.' Row 16: Row 17: Specificity Row 18: Kim ingevoerd) nodules nodules >of of ct(s) was justified. Rod(s):",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "headed headed <98, 98, n=21).>",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: 98, 98, n=21). Row 7: Row 8: Lin (22) respectable respectable HCC2(1/2 )",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "headed headed <98, 98, n=21).>",
      "text": "Row 1: Confidence interval) Row 2: Row 3: Row 4: Row 5: HCCs HCCs >METAVIR METAVIR fibrosis",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "headed headed <98, 98, n=21).>",
      "text": "Row 1: Confidence interval)' Row 2: Row 3: row 4: Road 5: Positive predictive value' ROW 6: KIM",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "headed headed <98, 98, n=21).>",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025 53/155 Row 4: Row 5:",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Rovir 1: Row 2: Road 3: Rov 4: Row Row 5: CT ROW 6: (0 concentraties N/ A) injection. injection. (04% CPMP/ 3736/ 03 18/ HCCs HCCs (1-2cm and >2cm, respectively) with MRI.' Row 40: Row 41: ~ Row 42: on on 13-05-2025 54/155' Row 43:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 1)",
      "text": "Row 1: Row Row 2: Row 3: PPV (95% CI) Row 4: ROW ROW 5: METnegatieve F0 100% (Row Row 6: METAVIR F0-191.7% (Row Row 7: METavir F0-287.5% (Row Row 8: METAVIR F0-385.7% (ROW ROW 9: Raw 10: >2ml 2ml 4ml",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 2)",
      "text": "Row 1: Row 2: CT Row 3: NPV (95% Row 4: row 5: 0)‡33.3% (0.01- Row 6: 0):†12.5% (0.00- Row 7: 8)† 12.5% (0.00- Row 8: 5)†69.2% (0.48- Row 9: row 11: 0038.2% (0.26- Row 12: 00)38.2% (0.22- Row 13: 00 33(Row 10:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 3)",
      "text": "Row 1: Row 2: Row 3: %CI) Row 4: Row 5: -0.91)‡ Row 6: -0.53)‡ Row 7: -0.13)‡ row 8: -0.86)† Row 9: Row 10: Row 11: -0.70)† Row 12: -0.66)† row 13: -0.50)† Row 14: 7-0.82) Row 15: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 4)",
      "text": "Row 1: Row 2: Row 3: Row 3: row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 28: Row 29: Row 30: Row 31: Row 32: Row 33:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: row 3: ROW 4: row row 5: Specificity Row 6: the the patients' al. al.",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Confidence interval) Row 2: Row 3: Row 4: Row 5: HCCs HCCs >METAVIR METAVIR fibrosis",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Confidence interval) Row 2: Row 3: Road 4: row 5: Row Row 6: Fischer (2015) imaging imaging features: Raw 7: ~ Row 8: 11 T1-intensity (hypointense): 0.69 (95%CI: 0.57-0.81). raw 9: 'T2-intensities (not isointensity): 0.64 (95%C.I.) disposal. disposal.",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: Road 3: row 4: Raw Raw 5: Lin ('0) and and >Row Row 6: row 7: ROW ROW 8: Fischer (2015) values values ofalfa(s) 2 2 (2 2 cm): 10 10 cm",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Rovir Rovir 2: MRI Row 3: PPV (95% CI) NPV (95% CI): Row 4: Row Row 5: METAVIR F0100% (0.03-1.00)‡ {0.03-(1.00) ‡ raw 6: METavir F0-1 100% (0.1dimethyl 50% (0.01-0.92) • Row 7: România Ro0-3-",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 1)",
      "text": "Row 1: Row Row 2: Lin (15) România România • tegelijkertijd tegelijkertijd • 645 645 • Co-ordination • Los Angeles • los Cyvron • Rome. • Paris • France • Portugal • Italy • Germany • surrounding areas •",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 2)",
      "text": "Row 1: Row 2: and and >Row Row 3: Row 4: Row 5: imaging features: Row 6: Row 7: Row 8: Row 9: Row 10: Row 12: row 12: 1-2cm 1-2cm & >ROW ROW 13: Row 14: HCC HCC ‡ 15: Row 16: RevMWEG RevMWEG 17: România România Rod:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 3)",
      "text": "Row 1: Row 2: s, Row 3: Row 4: row 4: row 5: row 6: row 7: row 8: row 9: row 10: row 11: row 12: s, row 13: row 14: and",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 3)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 4: Road 5: ‡ Row 7: Row 8: Row 9: lactation Row 10: Row 11: Row 12: † Row 13: 0,5% Row 15: * Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25: Row 26: Row 27:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 4)",
      "text": "Row 1: Row 2: Row 3: row 3: row 4: row 5: row 6: row 7: row 8: row 9: row 10: row 11: row 12: row 13: row 14: a row 15: row 16: row 17: row 18: row 19: row 20: row 21: row 22: row 23: row 24: row 25: row 26: row 28: row 29: row 30: row 31: row 32: row 33: row 27: row 47:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Veronica: Row 1: Row 2: ROW 3: row 4: Hepatocellular carcinoma' Row 5: theality theality ́Row 6: Row Row 7: consciousness. consciousness.",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: by Nadarevic (2022)); patients patients (for for imprecision: confidence confidence intervals); Row Row 7: Row 8: limitations limitations (the the patient's room; situation. situation.",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: I:multiphasic multiphasic CT-scan;Row 2: C:-;Row 3: R:Histology;'Row 4: O:value. value. −Row 5: −Row 6: Relevant measuresRaw 7: syndrome. syndrome.",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Road 4: row 5: Hepatocellular carcinoma' Row 6: being being <100% equal equal (n=49) velocity.",
      "start_page": 59,
      "end_page": 59
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 5: F",
      "start_page": 59,
      "end_page": 59
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 59/155",
      "start_page": 59,
      "end_page": 59
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: Row 4: The module 'Surgical intervention' sub sub modules: row 5: ~ row 6: − row row 7: ● row row 8: adequaat",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025 60/155",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 1)",
      "text": "Row 1: Row Row 2: Row Row 3: Row 4: The module 'row row 5: row 6: − row row 7: row row 8:",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 1)",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 2)",
      "text": "Row 1: Row 2: tie Row 3: Row 4:vention' row row 5: Row 6: tie Row 7: Row Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: entire Row 13: Row 14:",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: bmodu Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: ulcers: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: row row 13: Row 14:",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: produ Row 13: Row 14:",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: row 4: row 5: row 6: row 7: row 8: row 9: row 10: row 11: row 12: guess row 13: row 14:",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 10)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14: 60/155",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Raw Raw 2: Row Row 3: Rov 4: disease disease (liver liver cirrhosis) ROW ROW 8: Recommendation Row 9: Row 10: based based (and externally validated) Row Row 22: Row 23: patients patients (their their caregivers) Row 24: to to re-assess",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: row 3: row row 4: ROW ROW 5: interest interest (an an MDO). Road 15: Row 16: arrow arrow 17: 26 row 18: Rationale of recommendation: account account in",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: row 3: Row 4: • Hepatocellular carcinoma • Row 5: •reversible reversible • Row-retardation. •Row-Row-Raw-Low ratio •life life •Row Row 7: Conclusions /FINDINGSrow FINDINGSrow 9: cohort cohort (n=180) cohort cohort (1180). Row Row 32: Row 33: Only the preoperative## bewerkt bewerkt Rov& 37 row",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: row 3: row 4: row row 5: Yang (15) overall overall survival: AFP, AFP, μg/ L; Row 8 ≤20 (HR 1, reference) 20-400 20-400 (83 83 (95%2. 2.69)); Row 10 (95% 1, 1, rh) of of 3- head. head. # A. A. # Rovharde Lieberführer. # precautions. precautions.",
      "start_page": 64,
      "end_page": 64
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: Row 7: Row Row 8: Row 9: following following question: Row 10: carcinoma carcinoma (HCC):",
      "start_page": 65,
      "end_page": 65
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: I:or or overtreatment;' Row 2: C:no no comparison; Row 3: O:",
      "start_page": 65,
      "end_page": 65
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: T: After diagnosis; Row 2: S: here. here. ́ Row 3: Row 4: ROW ROW 5: models. models.' Row 17: Row 18: select select (Methods) Row 19: ~ Row 20: on on 13-05-2025 65/155 Row 21:",
      "start_page": 65,
      "end_page": 65
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: Medline Medline (via OVID) and Embase (via Embase.com) following following criteria: Row 6: •tablets. tablets.",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 5: B",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 66/155",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "• Raw Raw 2: • Row Row 3: Road 4: • study study • out. out. • surgery surgery (laparoscopy, laparoscopy, MIC) 9 9 • Row Row 24: Row 25: complications complications (≥ grade III) process process (Ding, 2022). whether whether Row",
      "start_page": 67,
      "end_page": 67
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Role 1: Row 2: Rov 3: Row Row 4: PFS PFS (91.8% versus 79.2% after 5 years); treatment. treatment. Row- question. question. Row-14: Row 15: Ding (2022) ablation ablation (MWD) and Rob- assisted liver re",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: see 'vs vs Resection",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: ROW 3: Row Row 4: the the benefit/ a a procedure;Raw Raw 16: Row 17: valid valid option; Row Row 18: Enbrel. Enbrel.",
      "start_page": 69,
      "end_page": 69
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: Road 3: Row Row 4: row 5: Row 6: Row Row 7: Cheng (2022)",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: Conticchio (2021)",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: Ding (2022)",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: Results row 3: Outcome 1- row row 4: Cheng (2022) resection resection (LLR) ablation ablation (RFA) Row-2015 Row-2015 Rovarian:",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: Road 5: ROW ROW 6: complications complications (Clavien- Dindo grade 3+) significant significant (p=0.574). Row 7: Row Row 8: following following reasons: Rov 14: ́of of 5'ratio ratio (Row and 4Red)",
      "start_page": 71,
      "end_page": 71
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: under Row 2: Row 3: row 4: Road 5: ROW ROW 6: Row 7: complications complications (Dindo, 2004). operation. operation.' Row 8: − Row 9: group group didn'Yang Yang (2021) it. it. #different. different. #Row 20: Row 21: Yang Yang (2021). death. death.",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row Row 2: Responsible Row 3: Row 4: row 5: Previously assessed 01-01-2024 Row 6: Last authorized: 01-01/2024",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 4: C",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 73/155",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row Row 2: (Non-surgical) Row Row 3: Row 4: The module '(Not Surgical) sub sub modules: Row 5: Radioembolisation Road 7: ~Row Row 8: ------------- Row Row 9: ≥Roy 10: Responsible Row 11:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "headed headed <98, 98, n=21).> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025 74/155",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 1)",
      "text": "Row 1: Row Row 2: (Non-surgical) localised Row 3: Row 4: The module '(Non-Surgical), localized-cartridge Row 5: Raw 6: 'Radioembolization Road 7: 'Row Row 8: 'Row Row 9: ~Row 10: Responsible Row 11: 'Row 12: Late rated 13: 01-01-2024:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 1)",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 2)",
      "text": "Row 1: Row 2: Eling Row 3: Row 4: division Row 5: Row 6: Row 7: tie Row 8: patients Row 9: Row 10: Row 11: Row 12: Row 13: table Row 14: Row 15:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 3)",
      "text": "Row 1: Row 2: g Row 3: Row 4: g: g' row row 5: Row 6: Row 7: Row 8: Row Row 9: Row 10: Row 11: Row 12: Row 13: Row Row 14: Row 15:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Row 6: Row 7: Row 8: Row Row 9: Row 10: Row 11: Row 12: Row 13: Row Row 14: Row 15:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: odule Row 5: Row 6: Row 7: Row 8: rrose Row 9: Row 10: Row 11: Row 12: Row 13: produ Row 14: Row 15:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: es: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row Row 14: Row 15:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Guess Row 14: Row 15:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "headed headed <98, 98, n=21).> (column column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row Row 14: Row 15: 74/155",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "headed headed <Radioembolization>",
      "text": "ROW 1: Raw Raw 2: Radioembolization Row 3: Row 4: ROW ROW 5: Row 6: ___MEDTERM0_ ___MEDTERM0_ TACE? Road 8: Recommendation Row 9: ~ ROW 10: center center ___>differed differed (ilijmrity) measure measure (imprecision), of of Rod-65",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row Row 3: row 4: row row 5: care care (comparative) arm arm (TARE) patients patients (BCLC A, n=27; BCLC B, n=68; BCL C, n=114), in in 62% months months (95%CI = 16.4 months)(Lam, 2022). e. e., yttrium-90 yttrium-90 (90) enrolled enrolled 41/of of >7 cm;of of <=stages stages (without PVT), TACE-15. TACE-15.",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Road 3: row 4: Row Row 5: cm cm (Salem, 2021) . Tms Tms .cm cm (Llovet, 2002) cm cm (Lo, 2002 . ___MED® . treatments treatments (by by Row-A-D-R-from from ROW-better better risk-of of Tab-rate rate of",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Road 3: ROW ROW 4: Raw Raw 5: 7 7 recommended: size size (>5 cm) of of > chemo-embolism chemo-embolism (TACE). Row 18: Row 19: Conclusions/ ROW ROW 20: rod - ROW 21: Row Row 22: ́Radioembolization (TARE) chemoembozation chemoembozation (TAE) Row-A, Row-A, row-",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "ROW 1: ROW 2: Row 3: row 4: Row Row 5: Radioembolization (TARE) chemoembolism chemoembolism (TACE) Road Road 6: Raw Raw 7: ~ ROW 8: ́ ROW 9: roviž Source ́Rowdale Rowdale ́t",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Kolligs (2015)",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: on on 13-05-2025 79/155 Row 2: Row 3: Row 4:",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: group group (65. 65.8±6.7; 85% male) group group (66. 66.7±9.0; 87% male). Row Row 7:",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Salem (17)",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Yang Yang (2020). Row 3: Row 4: Dhontt (2022)",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Results Row 3: control control (critical) Row 4: monitoring. monitoring.' Row 5: row 6: Kolligs (2015",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Progression Progression (Salem, 2016) Row 3: Road 4: on on 13-05-2025 80/155 Row 5: row 6:",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: row 3: row 4: row row 5: CharacteristicTARE (n=23)cTACE (n=19). Row 6: WHO1 (4%)5 (26%) Row 7: EASL0 (0%)8 (42%) Row 8: New hepatic lesions1(4%)6 (32%). Row 9: Out-hepatic metastases0 (11%) ROW 10: Row 11:",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: was was 87% (20/23 patients) and and 74% (14/19 patients)13. 13.3%, Row Row 3: Row 4: Dhontt (2022)",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Success rate ('critical) Row 3: downstaging downstaging and/Row Row 4: row 5: Kolligs (2015)",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row Row 3: row 4: Salem tussenpozen",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Dhontt (2022)",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Overall survival(contributory) Row 3: on on 13-05-2025 81/155 Row 4: row 5:",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Row Row 6: Row 7: Kolligs (2015)",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Pitton (2015)",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Salem (17)",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Dhontt (2022)",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Progression-free survival( Important) Row 3: reported reported progress- free survival (___MEDTERM0_). Row 4: row 5: Kolligs (2015)",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Pitton (2015)",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Dhontt (2022)",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: progression progression (TTP). Row 3: Row 4: Salem",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Complications( Important) Row 3: Row Row 4: Road 5: row 6: on on 13-05-2025 82/155 Row 7: ~ row 8: =",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Kolligs (2015",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Salem (2015)",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Pitton (2015)",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row Row 3: GRADE. GRADE. (Row 4: Row Row 6: consciousness consciousness (the the level) (film-coated film-coated radiology). low. low.' Row 16: Row 17: Row Row 18: limitations limitations (bias bias (see RoB assessment), Row 19: -Row 20: on on 13-05-2025 83/155:",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Road 3: row 4: Row Row 5: -1), indirectness (-1; control control group) patients patients (imprecision, -1). Row Row 6: Row 7: Complications Row 8: old old (respiratory distress syndrome) (routcome measurements) (the the patient's condition) ( Row Row 9: Row 10: roof roof ́sMC-Rmeenschappelijke Roof mexico'following following question: − Row 13: radioembolization radioembolization (TARE) chemoembolisation chemoembolisation (TACE) BCLC BCLC stage",
      "start_page": 84,
      "end_page": 84
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Road 4: row 5: Hepatocellular carcinoma' Row 6: Overallsurvival: Absolute difference >5% difference difference >3% ratio ratio (HR) <beam. beam.",
      "start_page": 85,
      "end_page": 85
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 5: B",
      "start_page": 85,
      "end_page": 85
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: on on 13-05-2025 85/155 Row 2: Row 3:",
      "start_page": 85,
      "end_page": 85
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Rolland Rolland Y; carcinoma carcinoma (DOILAG-12phere-01):",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 86/155 Row 3:",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: PMCID: PMC5124387. Row 6: S",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 87/155",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: Row 4 : 6 6 : or or ablative? Road 7 : Row 8 : 9 9 : Row 10 : toablation toablation (6 6 weeks) in patients {_MEDTERM0 ); differed differed (indirectness) measure measure (imprecision), very very low",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "ROW 1: Row 2: Road 3: row 4: row row 5: arrow arrow 6: row 7: assessment assessment (rather than placebo) assessment assessment (Rather than comparators) either either treatment",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "ROW 1: Row 2: row 3: row row 4: arrow arrow 5: Road 6: Rationale of recommendation: interventionsarrow interventionsarrow 7: a a hard-care care (p = Row Row 8:attained attained RowTer'is is not",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: row 5: Row Row 6: ́8 8 : disease Sources: bed. bed.",
      "start_page": 91,
      "end_page": 91
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Liu opkomen",
      "start_page": 91,
      "end_page": 91
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 91/155 Row 3: Row 4:",
      "start_page": 91,
      "end_page": 91
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: male). Row Row 7: Row 8: Liu",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Morimoto TRANSITION",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Peng schema",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Peng",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Sheta (2016",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Zaitoun (2021)",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Li Li (2021). Row 3: Row 4: Zhang (2021)",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Results Row 3: Overall survival (critical) Row 4: row 5: on on 13-05-2025 92/155 Row 6: Road 7:",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: survival survival (by by RowterM0_). of of monotherapy: the the __MEDTERM0; group group (2. 2.1) other. other.",
      "start_page": 93,
      "end_page": 93
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: raw 2: row 3: row 4: row row 5: Row 6: ́ Row 7: ~ Row 8: Z: pooled pooled effect; df: freedom, freedom, I2: statical heterogeneity, CI: Row Row 9: − Row 10: Disease-free survival (critical) Row 11: group group (DF- beschikbaar) − A. A.",
      "start_page": 94,
      "end_page": 94
    },
    {
      "heading": "headed headed <Radioembolization> (column column 1)",
      "text": "Row 1: Row Row 2: Row 3: row 4: Road 5: Z: pooled pooled effect; df: freedom, freedom, I2: static heterogeneity, CI: confident Row 6: ROW 7: Disease-free survival (critical) Row 8: disease-freesurvival disease-freesurvival (DFS). time time (ADFs) .",
      "start_page": 94,
      "end_page": 94
    },
    {
      "heading": "headed headed <Radioembolization> (column column 2)",
      "text": "Row 1: row 2: Row 3: Row 4: Row 5: Row Row 6: ROW 7: ~Row 8: groupRaw groupRaw 9:",
      "start_page": 94,
      "end_page": 94
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: row 3: Row 4: ROW ROW 5: Outcome Outcome 1-, 3-, 5-, with with TACE+Row Row 6: Gaulle Gaulle (Row de Rome) study study (Zhang, 2021), 47.9% group group (48/95) and 72.6% group group (694/progression. progression.' Row 23: Row 24: Complications (importment) Row 25: ROW ROW 26: # ROW 27: ####",
      "start_page": 95,
      "end_page": 95
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: Road 5: ROW ROW 6: (1.4%). group group (1.4%). relevant. relevant.' Row 8: 2. 2.1% group group ( GRADE. GRADE.' Row 18: Row 19: Overall survivall' Row 20: limitations limitations (bias, bias, -1 (see RoB assessment)) nerves nerves (respiratory distress syndrome) (i.e., problem. problem.",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: row 3: row 4: Road 5: Row Row 6: (imprecision, -1). Row Row 7: Raw 8: Row Row 9: ~ Row 10: following following question: − ROW 8: the the effectess-A-C-R-E ratio:",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row Row 3: equal equal equal? to to + following following criteria:' Row 21: Row 22: ́trials. trials.' Row 23: ~ Road Road 24: − criteria. criteria. − Row 25: ● Row 26: on on 13-05-2025 97/155 Row 27:",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: row 3: row 4: row row 5: 50-excluded excluded (tab tab methods). waspakken. waspakken.",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 5: B",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 98/155 Row 3:",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: P",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 99/155",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: Row 4: • Row Row 5: ROW 6: ___MEDTRM0_ ___MEDTRM0_ EMEA/ CPMP/ 3736/ 03 18/ is is eligible: 6cm 6cm . RowT is not",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: row 3: row row 4: cost cost (means recovered) Raw 5: the the benefit/ Row Row ́Row Row 20: Row 21: Conclusions / Row Row 22: ~ Row 23: ROW ROW 32: row-2015 Row-",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: row 3: Row 4: 5 5 2022: Row Row 31: Row 32: Row Row 33: Méndez-Romero Méndez-Romero (2023), arm arm (beads beads and) place. place.",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "ROW 1: ROW 2: Row 3: row 4: Road 5: Raw Raw 6: multiple multiple TAE/al. al., months months (95% to to 53) months months (95% CI 1735) into the TAE/TACE arm (p = 0.472). was was 75% and 64% armand armand 95% and 57% Row Row 19: Rov 20: grade grade >arm. arm.' Row 26: Row 27: on on 13-05-2025 103/155 Row 28: ~ Row 29:",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Road 3: row 4: Row Row 5: row 6: Row Row 7: function. function.' Row 8: ~ Row 9: Row Row 10: 3 3 level",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: 3 3 level",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: 3 3 level",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row Row 3: Row 4: following following question: Row 5: Row 6: P:",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: I:therapy therapy (SBRT);Row 2: C:optionsRaw optionsRaw 3: O:function. function.'Row 4: −Row 5: Relevant measures - Row 6: and and over- recurrception ratio - Row 4:",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: row 3: row 4: Road 5: row row 6: excluded excluded (tab tab Method), included. included.",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 4: C",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 105/155",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: Row 4: sub sub modules: row 5: ~ row 6: − Trans-arterial radioembolization (TARE) row row 7: ● patients patients − ____",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025 106/155",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "headed headed <Radioembolization> (column column 1)",
      "text": "Row 1: Row Row 2: Row Row 3: Row 4: 5 5 module: row 6: Row Row 7: systepatile systepatile HCC? Road 8:",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "headed headed <Radioembolization> (column column 1)",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "headed headed <Radioembolization> (column column 2)",
      "text": "Row 1: Row 2: linge Row 3: Row 4: trade Row 5: Row 6: mbolisa Row 7: emthe Row 8: Row 9: Row 10: Row 11: Row 12: order Row 13: Row 14:",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "headed headed <Radioembolization> (column column 3)",
      "text": "Row 1: Row 2: and Row 3: Row 4: Ling' row row 5: Row 6: ation (TARE) Row Row 7: Row Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "headed headed <Radioembolization> (column column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Row 6: mtherapy Row 7: Row Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "headed headed <Radioembolization> (column column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Module Row 5: Row 6: Row 7: Row Row 8: Row 9: Row 10: Row 11: Row 12: row row 13: Row 14:",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "headed headed <Radioembolization> (column column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: es: Row 5: Row 6: Row 7: et one (not Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "headed headed <Radioembolization> (column column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: row 4: row 5: row 6: row 7: row row 8: row 9: row 10: row 11: row 12: row row 13: row 14:",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "headed headed <Radioembolization> (column column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: manageable)- Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14: 106/155",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "ROW 1: ROW ROW 2: Trans-arterial radioembolization (TARE) Row Row 3: Raw 4 : 5 5 : Row 6 : patients patients {_MEPTRM4 } a a ́to to ́there there ́? Raw 8 : Recommend ́ 10 10 : measure measure (imprecision), patients patients 24/ in in patients",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "ROW 1: ROW 2: Row 3: row 4: Hepatocellular carcinoma' ROW 5: Road Road 6: studies studies (__MEDTERM0_) analysis analysis (Cheng, 2022). individual individual patient'therapy therapy (Pfister, 2021; 948 948 dollars/effective effective (Row Row 13: Row 14: - Row 15: on on 13-05-2025 108/155 Row 16:",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Road 3: row row 4: row row 5: Row Row 6: row 7: Rationale of recommendation: row row 8: with with Row- Row Row 15: Row 16: Conclusions / ROW ROW 17: (Row 18: Overall survival (crucial) Raw 19: ́TARE TARE (using using BSA-_MEDTERM0_hod) patient patient ́s Row accessory: 4 4 cm",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: ROW 3: row 4: Raw Raw 5: TARE TARE (using using BSA-method) Row Row RAY:",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Vilgrain (2017) SARAH",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Pereira (2021) SARAH",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: on on 13-05-2025 110/155 Row 2: Row 3: Row 4:",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: Road 5: ROW ROW 6: SIRT SIRT (n=122) or __MEDERM___(n=163). of of Rowmet'Row Row 17: Row 18: Progression-free survival (___",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: Road 5: ROW ROW 6: 23/198 (12%) complete complete (n=2) response response (nt=21) (63, 63, 95% 2. 2.65; 07, 07, 95% 0. 0.14)). Row Row 7: raw 8: level level (level level 2) limitations limitations (bias, bias, -1 (see RoB assessment)) patients patients (imprecision, -1). . low. low. .Row 21: Life Life (important)Row 22: of of Sponsor-Methessie-Mye syndrome.",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: row 2: Row 3: Row 4: Hepatocellular carcinomaRaw 5: ROW 6: limitations limitations (bias, bias, -1 (see RoB assessment)) patients patients (imprecision, -1) measures measures (indirectance, -1). Row Row 7: Row 8: Row Row 9: ́ Row 10: following following question: with with disease; row",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: Raw Raw 6: user user (RPVMan) ratios ratios (RRs) differences differences (RDs) rate rate (MDs) tables. tables.' Row 23: Row 24: Responsible Row 25: ~ Row 26: Last evaluated: 01-01-2024 Row 27: Last authorized 01-01/2024",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 4: A",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: on on 13-05-2025 114/155 Row 2: Row 3:",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Group Group (2018). __",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: oclc. oclc.org/10.1016/Row Row 2: P",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: 2045(17)30683-6 Row 2: Row 3: on on 13-05-2025 115/155",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "ROW 1: Row Row 2: a a (not locally treatable)-HCC? Row 3: Row 4: Row Row 5: row 6: manageable manageable HCC? Raw 7: • Recommendation Row 9: − ROW 10: Road Road 17: Row 18: ROW ROW 20: on on ___DDERM2/syndrome syndrome . Raw Raw 20: In the",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: __MEDTERM0_ __MEDTERM0_ +the the {months }trial trial (RowterM2+) ROW ROW 10: Row 11: Row Row 12: patients patients (their their caregivers)' ROW 13: the the patient'limited limited to",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: ROW 2: Row 3: row 4: row row 5: so. so. ~Row Row 17: Row Row 18: Raw Raw 19: the the Recommendation: Row Row 21: s s pharmacokinetics",
      "start_page": 118,
      "end_page": 118
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Veronica: Row 1: Row 2: Row Row 3: Conclusions / ROW ROW 4: row 5: Raw Raw 6: Conclusions Row 7: Overall survival (crucial) Row 8: placebo placebo 9: ~Treatment with ~hepato. hepato. Row_M",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "headed headed <Radioembolization> (column column 1)",
      "text": "ROW_ 1: ROW ROW 2: Conclusions /Row Row 3: Row 4: Rrow Rrow 5: Conclusions Row 6: Overall survival (crucial)(Row 7: Raw Raw 8: in in patients; Row_A/Q.",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "headed headed <Radioembolization> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row Row 9: Row 10: Row 11: Row 12: Row 13: survival",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "headed headed <Radioembolization> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: al",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "headed headed <Radioembolization> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: ree survival",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "headed headed <Radioembolization> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: n-free",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "headed headed <Radioembolization> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: Row 7: Row 8: Row 9: Row 10: 119/155",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Veronica: ROW 1: ROW 2: Row 3: row 4: Row Row 5: Row Row 6: Row Row 7: Raw Raw 8: ~Row 9__ng_",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: Road 6: ~ versus versus {IMEDTERM2 } Rowter-Cr(S)",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: row 3: row 4: ROW ROW 5: hepatocellular hepatocellular carcinoma(ROW-ROW) (ROW, ROW 7: ~8 8 Sources: (Brux, 2017)Raw 9:",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: events ( Important), life life (important) Row 2: -Row Row 3: GRADE Row 4: Row 5: Row Row 6: Row 7: Park (2021)",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Oranratnachai (2021)",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Solimando (2022)",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: on on 13-05-2025 122/155 Row 2: Row 3: Row 4: Row 5:",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: clinical clinical outcomes: __",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025 123/155 Row 4: Row 5: Row 6:",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "ROW 1: ROW 2: row 3: Row 4: Road 5: Raw Raw 6: RCTYearTrial/20 20 MED_M_Q%-10) RovvetSHARPIII QRF_QQD%S.",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025 124/155 Row 4: Row 5: Row 6:",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (column column 1)",
      "text": "Row 1: Hepatocellrow 2: RCTrow 3: row 4: Llovetrow 5: Chengrow 6: CheNGrow 7: Johnsonrow 8: Zhurow 9: Cainaprow 10: Cheungrow 11: Kudorow 12: KuDOrow 13: Yaurow 14: Abu-Alfarow 15: Finnrow 16: Row the 17: Bi and Qin*raw 26: Row 27: Lairow 24:",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (column column 2)",
      "text": "Row 1: Row Row 2: Year Trial/Ph Row 3: Row 4: Row Row 5: Row Row 6: ́Raw Raw 7: n2013 BRISK-Fraw 8: ~2015SEARCH Raw 9:",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (column column 3)",
      "text": "Row 1: Row 2: Row Row 3: row 4: P/IIISora Row 5: 0492752/Row Row 6: 70/Row Row 7: FL/III-Briv Row 8: H/III 'Erlo Row 9: 009593/IIILinif Row 10: 033240/IITiga Row 11: 400788/IIResm Row 12: CT/III -Len Row 13: Mate 459/IIINivel Row/Sun Row farm",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (column column 4)",
      "text": "Row 1: Row 2: ervention Row 3: row 4: afenib# ROW 5: __ gewetenTM0_# Row 6: ____49TM2_# Road 7:_тEDTERM3__~ROW 8:__MEDTERM4_ + Sor_MEDERM0_~Row 9:_MEDDERM6___ROW 10:_siterm7__ +Sora_Row_M_",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (column column 5)",
      "text": "Row 1: Row 2: Row 3: row 3: row 4: row 5: row 6: row 7: row 8: b row 9: row 10: ____MEDTERM0_ROW 11: ________________EDTERM1___ROW 12: row 13: row 14: ubicin row 15: row 16: row 17; row 17: row 18: row 20: row 21: row 22: row 24: row 25: row 26: row 27: row 28:",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (column column 6)",
      "text": "Row 1: Row 2: Compar Row 3: row 4: Placebo Row 5: Placebo Row 6: row row 7: ~Sorafeni Row 8: •Sorafeni row 9: −Soradeni row 10: bSoraveni row 11: =Sorageni row 12: safety. safety.",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (column column 7)",
      "text": "Row 1: Row 2: row row 3: row 4: row row 5: o226 row 6: row row 7: row row 8: row row 9: row row 10: Row Row 11: ici - 12: row row 13: row row 14: row row 2: 945 945 rod",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (column column 8)",
      "text": "Row 1: Row 2: ParkOra Row 3: (2021)(20 Row 4: XRow 5: XRow 6: X'Row 7: X-Row 8: X -Row 9: X\"Row 10: X≥Row 11: X ≥Row 12: X<Row 13: X=Row 14: X>Row 15: X INCREW 17: X±Row 18: X/Row 27: ROW 20: ~Row 29:",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (column column 9)",
      "text": "Row 1: Row 2: anratnachai Row 3: 021) Row 4: X Row 5: X Row 6: X Road 7: X row 8: X ROW 9: X RUW 10: X ROW 11: Row 12: XROW 13: Row 14: X row 15: Row 16: Row 17: Row 18: Row 18: Row 19: Xrow 20: Row 21: Row 22: XRow 23: X-ROW 24: X - 35 ROW 25: X OW 28: X WOW 27: ROW 27:",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (column column 9)",
      "text": "Row 1: Row 2: 124/155",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Road 4: 6 6 ́ R herkend Trial/8 8 RESORCE/III necrosis/13 13 M2",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "headed headed <Radioembolization> (column column 1)",
      "text": "ROW 1: Row Row 2: RCTYearTrialPaseInterv Row 3: 4 4 ́RovWEG-T)was was Row45RovwegRaw45A/QEELSTIAL/Raw15 Raw15 Raw12B/QNIT) Ravmax, Ravmax, Rov",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "headed headed <Radioembolization> (column column 2)",
      "text": "Row 1: Row 2: Row Row 3: row 4: Row Row 5: -------------",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "headed headed <Radioembolization> (column column 3)",
      "text": "Row 1: Row 2: Row Row 3: (2021) Row 4: rod 4: bo 573 X: Raw Raw 6: Row Row 6: ROW ROW 6: 645 645 row: • X X : o/",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: patients patients with",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: (unresectable) HCC? Row 2: __",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Cheng",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: __MEDTERM0_ +row row 3: Finn (2020) IMbrave150",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: row row 3: Kudo (2018) REFLECT",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: on on 13-05-2025 126/155 Row 2: Row 3: Row 4:",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: __MEDTERM0_ __MEDTERM0_ (12 mg/bodyweight bodyweight ≥8 8 mg/body body weight) (n=478) patient. patient.",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: (unresectable) HCC? Row 2: Row Row 3: Bruix (2017) - RESORCE",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: patients patients with",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: (unresectable) HCC? Row 2: with with (unresectable) Row Row 3: Row 4: both both second- and third- line treatment were",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: efficacies. efficacies.' ROW 2: Row Row 3: Overall survival (_MEDTERM1_) (crucial)(Row 4: placeboRow placeboRow 5: Two studies (Llovet, 2008; Cheng, 2009) Road Road 6: Rov 7: Llovet",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: limitations limitations (bias, bias, -1 (see RoB assessment) not not __MEDTERM9_'s (imprecision, -1). __MEDTERM9_ __MEDTERM9_ (imprecision, -2). outcome outcome overallsurvival' equal. equal.",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: row row 5: Cheng (2022) median median -65 65 (95% 0. 0.81). relevant. relevant.' Row 6: 2 2 (Red) group group 7/299 (2.3%) with with 2/303 (0.7%) 1. 1.7% (95% CI -3. 3.6). Row Row 21: ROW 22: Cheng",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Road 4: row 5: ROW ROW 6: (0.6%) and and 17/159 (10.7%) was was 97/326 (29.8%) to to 18/159 (11.3%) 18. 18.4% (95% 25. 25.4). low. low.' ROW 15: Row 16: events events (important) Row 17: ROW ROW 18: Two studies (Llovet, 2008; Cheng, 2009) Road Road 19: ́Rovert-ragent tre.",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: Road 6: limitations limitations (bias, bias, -1 (see RoB assessment)) events events (imprecision, -2). low. low.' Row 7: relevant. relevant.' Row 17: Row 18: Row Row 19: __MEDTERM14_ __MEDTERM14_ (imprecision, -2). 20___ 20___ Row?",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: Road 5: ROW ROW 6: months months (95% not not iedereen), months months (95%7. 7.0) (73, 73, 95% 0. 0.85) (ROW ROW 16: Row 17: Row Row 18: Overall survival (___MEDTERM11_) (crucial) Row 17: important important question:",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: not not (imprecision, -2). survival survival Row? was was -2.6% (95% CI -6. 6.0). relevant. relevant.' Row 19: Row 20: Row Row 21: RCT. RCT. #not not __",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Veronica: Row 1: Row 2: Row Row 3: Row 4: Road 5: following following question: • Row 6: with with (unresectable) HCC? Row 7: ROW 8: PICO ROW 9: P: Non-others. others.",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "headed headed <Radioembolization> (column column 1)",
      "text": "Veronica: Row 1: Row Row 2: Row 3: Row 4: following following question: (Row 5: with with (unresectable) HCC? row 6: Road 7: PICO ROW 8: P:non-nausea nausea : • syndrome syndrome • failure failure • failure. failure.",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "headed headed <Radioembolization> (column column 2)",
      "text": "Row 1: Row 2: Row 3: row 3: row 4: row 5: row 6: row 7: row 8: row 9: row 10: row 11: row 12: row 13: row 14: row row 15: row 16: row 17: row row 18: isease row 19: row 20: row 21: row 22: row 24: row 25: or: row 26: row 27: row 41: row 28: row 23:",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row 2: Row 3: row 4: ROW ROW 5: Medline Medline (via OVID) and Embase (via Embase. com) Row Row 20: Row 21: Netherlands Netherlands are: Row 22: ~ Row 23: -------------_MEDTERM0_. Row 24: ----------------_MEPTERM1__ +__MEMTRM2_.' ROW 25: ________________MEPTERN3_. row 26: − row 27: = 2nd- Late Late 32: ____ Rowd-",
      "start_page": 135,
      "end_page": 135
    },
    {
      "heading": "headed headed <Radioembolization> (from previous page)",
      "text": "Row 1: Row Row 2: on on 13-05-2025 135/155",
      "start_page": 135,
      "end_page": 135
    },
    {
      "heading": "headed headed <References>",
      "text": "Row 1: Row Row 2: References Row 3: Row 4: A",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "headed headed <References>",
      "text": "Row 1: Row 2: on on 13-05-2025 136/155 Row 3:",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "headed headed <References> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: F",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "headed headed <References> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 137/155 Row 3:",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "headed headed <References> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: cncr2820620306>3.0.co;2l. PMID: 2839280. Row 6: Ll",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "headed headed <References> (from previous page)",
      "text": "Row 1: on on 13-05-2025 138/155 Row 2: Row 3:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "headed headed <References> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: advanced hepatocellular carcinoma: 2013 2013 Jan;14(1):55-63. doi: 10.1016/S1470-2045(12)20. 20. PMID: 23182627. Row 6: S",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "headed headed <References> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 139/155",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "headed headed <the the follow>",
      "text": "Row 1: Row Row 2: Aftercare Row 3: Row 4: sub sub modules: row 5: − Row 6: ● Row Row 7: (2) Row Row 8: ♦Row 9: Responsible Row 10: adequaat 11: Last assessed: Road 12: Last authorized:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow>",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025 140/155",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow> (column 1)",
      "text": "Row 1: Row Row 2: Aftercare Row 3: Row 4: Row Row 5: Row 6: Row Row 7: ~Row Row 8:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow> (column 1)",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Row 6: Row 7: Tie Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow> (column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: modules: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow> (column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: entire Row 13: Row 14:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow> (column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow> (column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: row row 13: row 14:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow> (column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <The 'After care' the the follow> (column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: produ Row 13: Row 14:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow> (column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow> (column 10)",
      "text": "Row 1: Row 2: Row 3: Row 4: row 4: row 5: row 6: row 7: row 8: row 9: row 10: row 11: row 12: guess row 13: row 14:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <the the follow> (column 11)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row Row 13: Row 14: 140/155",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "headed headed <first first year>",
      "text": "Rov 1: Hepatocellular carcinomaROW 2: yearRov yearRov 3: Row 4: to to include: Row Row 19: Row 20: appetite, appetite, nausea/ loss loss (Sun, 2008).",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "headed headed <first first year> (from previous page)",
      "text": "Row 2: row 3: row row 4: arrow 5: care care (2017), diseases diseases (Demark-Wahnefried, 2006). Row Row 13: Treatment Row 14: ROW ROW 15: row 16: in in patients",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "headed headed <first first year> (from previous page)",
      "text": "Row 1: Row 2: row 3: row row 4: cancer cancer (as as psychosocial) row row 5: row 6: Substantiationrow 7: Backgroundrow 9: −row 10: to to 15",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "headed headed <first first year> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 4: D",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "headed headed <first first year> (from previous page)",
      "text": "Row 1: substance-based. substance-based. 2007; Row Row 2: 2019. 2019.' Row 3: https://guidelines Database.nl/ guideline/treatment_of_pain_patients_____________________ generally_cancer/ Road Road 4: NRow 5: https://ncdietish guideline/",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "headed headed <first first year> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 143/155",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "headed headed <first first year> (column column 1)",
      "text": "Row 1: Row Row 2: cancer cancer (psychosocially psychosocially both) Row Row 3: Row 4: Undergoing Row 5: row 6: Background row 7: 13 13 ROWAL-",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "headed headed <first first year> (column column 1)",
      "text": "Row 1: Row Row 2: Row 3: References Row 4: Row 5: D",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "headed headed <first first year> (column column 1)",
      "text": "Row 1: content. content. 2007; Roy Roy 2: Pain Pain _____cancer/policy_suitary_b'Row 4: NRow 5: gepoold/treatment/pain_Patients__",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "headed headed <first first year> (column column 1)",
      "text": "Row 1: Row 2: on on 13-05-2025",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "headed headed <first first year> (column column 2)",
      "text": "Row 1: Row 2: k.Raw 3: Row 4: row 5: ROW 6: ~Row 7: −Row 8: detectionROW detectionROW 9: ●Row 10: ♦Row 11: grofRow 12: ↔ pertise pertise group'Row 13: phenoxyRow 14:",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <cancer cancer manifestations>",
      "text": "department department immediately: be be performed: Sixty-eight patients (45%) developed;patients patients (55%) Plan Plan (RMP) 8. 8.2",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <cancer cancer manifestations> (from previous page)",
      "text": "Use Use (CHMP) the the alpha-Feto-Protein (AFP) Row Row 24: Row 25: Recommendation-1 row 26: the the recommendation: row row 27: __MEDTERM0_ __MEDTERM0_ (suspected upon) the the physician",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <cancer cancer manifestations> (from previous page)",
      "text": "Row 1: Row Row 2: Substantiation Row 3: Road 4: Row 5: Background row 6: row 7: Row Row 8: − Row 9: Row Row 10: ~ Row 11: be be qualified",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <cancer cancer manifestations> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: References Row 4: Road 5: content. content. 2007; Row Row 6: H",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <cancer cancer manifestations> (from previous page)",
      "text": "Row 1: Row 2: on on 13-05-2025 146/155",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <module module isa>",
      "text": "Row 1: Row Row 2: Row Row 3: Row 4: sub sub modules: row 5:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <module module isa>",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025 147/155",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column 1)",
      "text": "Row 1: Row Row 2: Row Row 3: Row 4: row row 5: row 6: row row 7: phase phase 8: Row Row 9:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column 1)",
      "text": "Row 1: Row Row 2: Row 3: on on 13-05-2025",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5: Row 6: Row Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row Row 14: Row 15:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: row row 5: Row 6: row row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: row row 14: Row 15:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "headed headed <The 'Organization of Care' module isa> (column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: ub modules: Row 5: Row 6: Row Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row Row 14: Row 15:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: : Row 5: Row 6: algnit row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: vervain Row 14: Row 15:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: teet (HCC) Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row Row 14: Row 15:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: row 4: row 5: row 6: row 7: row 8: row 9: row 10: row 11: row 12: row 13: row row 14: row 15:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Guess Row 14: Row 15:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exista> (column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row Row 14: Row 15: 147/155",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exista> (from previous page)",
      "text": "Row Row 2: malignancy malignancy (HCC) following following reasons: time time as",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exista> (from previous page)",
      "text": "Row 1: a a patient;_MEDTERM0_ (suspected by) Row 2: abnormality abnormality (HCC): Row 3: abnormality abnormality (HCC). Row 4: Row 5: Row Row 6: are are minimal: row 7: row 8: • rod rod 9:",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exista> (from previous page)",
      "text": "the the benefit/ Role Role 17: Management Role 18: Row Row 20: needs needs and",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exista> (from previous page)",
      "text": "Row 2: Raw 3: row 4: • the the ́tumours tumours (multidisciplinary multidisciplinary discussion) making making & goal goal (KNMG, 2022). Row Row 18: raw 19: Building row 20: 26 row 21: Background row 22: - Row 23: address address the",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exista> (from previous page)",
      "text": "Row 1: Row 2: Row Row 3: row 4: Row Row 5: Road 6: Responsible Row 7: ~ Row 8: Last assessed 01-01-2024 Road 9: Last authorized 01/01-2024",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exista> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: References Row 4: row 5: 2022. 2022.https://www.kng.nl/ consulting guidelines/ dossiers/informed-consent Road 6: S",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exista> (from previous page)",
      "text": "Row 1: N Row 2: https://puc.government.nl/nza/doc/PUC_2034_22/1/row 3: Row 4: on on 13-05-2025 151/155/55",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column column 1)",
      "text": "Row 1: Row Row 2: Row 3: Row Row 4: row 5: Responsible Row 6: Road 7: Last assessed 01-01-2024 Row 8: Last authorized: 01-01/2024",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column column 1)",
      "text": "Row 1: Row Row 2: Row 3: Row Row 4: row 5: 2022. 2022.https://www.kng.nl/ad Row 6: S",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column column 1)",
      "text": "Row 1: N Row 2: https://puc.government.nl/nza/doc/PUC_2034_22/1/row 3: Row 4: on on 13-05-2025",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: Row 5: Row 6: Row 7: Row 8: Row Row 9: Row 10: Row 11: Row 12: dvies guidelines/files/inform Row 13: Row Row 14: Row Row 15: Row 16:",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column column 3)",
      "text": "Row 1: row 2: Row 3: exprow exprow 4: ROW 5: Row 6:",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <The module 'Organization of Care' exists> (column column 4)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: Row 5: Row 6: Row 7: Row 8: Row Row 9: Row 10: Row 11: Row 12: Row 13: SONCOS Row 14: Row 15: Row 16: 151/155",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "headed headed <Recommend-1: Organizational Treatment Phase>",
      "text": "Row Row 2: row row 3: Row 4: community. community. • If the benefit/ patient patient • machines machines • machines machines (this this product) • problems problems (alcohol alcohol consumption) (Fernández, 2022).row 20: row 21: patientsrow patientsrow 22: party, party,",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "headed headed <Recommend-1: Organizational treatment phase> (from previous page)",
      "text": "Row 1: Row 2: row row 3: Background row 4: row 5: Row Row 6: Road 7: Row Row 8: - Row 9: justified. justified.",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "headed headed <Recommend-1: Organizational treatment phase> (from previous page)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row 5: F",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "headed headed <Recommend-1: Organizational treatment phase> (from previous page)",
      "text": "Row 1: 2023. 2023.https://lc.rivm.nl/ guidelines/hepatitis-b. Row 2: Row 3: on on 13-05-2025 153/155.",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "headed headed <Recommend-1: Organizational treatment phase> (column column 1)",
      "text": "Row 1: Row 2: row row 3: Background row 4: row 5: row row 6: ro 7: row row 8: − row 9: cow cow 10: ~ row 11: Responsible row 12: ? row 13: Lately assessed 01-01-2004:",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "headed headed <Recommend-1: Organizational treatment phase> (column column 1)",
      "text": "Row 1: Row Row 2: Row 3: References Row 4: Row 5: F",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "headed headed <Recommend-1: Organizational treatment phase> (column column 1)",
      "text": "Row 1: 2023. 2023. https://lci Row 2: Row 3: on on 13-05-2025",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "headed headed <Recommend-1: Organizational treatment phase> (column column 2)",
      "text": "Row 1: Row 2: row 3: row 4: arrow 5: Row Row 6: Road 7: ~ Row 8: − Row 9: Row Row 10:",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "headed headed <Recommend-1: Organizational treatment phase> (from previous page)",
      "text": "has has Row? Page Page 2/ package package leaflet: Page Page 2/ Row Row 33: physician. physician.' Row 34: Row 35: Row Row 36: Road Road 37: - Row 38: - ROW 39: on on 1305-25:",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "headed headed <Recommend-1: Organizational treatment phase> (column column 1)",
      "text": "with with Row- as as follows: medicinal medicinal product: Row Row 34: Row 35: Row Row 36: guidance. guidance.' Row 37: ~ Row 38: ? Row 39: on on 13-05-2025",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "headed headed <Recommend-1: Organizational treatment phase> (column column 2)",
      "text": "Row 1: Row 2: Row 3: row 3: row 4: row 5: row 6: row 7: row 8: row 9: row 10: row row 11: row 12: row 13: row 14: row 15: row 16: row 17: row 18: row 19: row 20: row 21: row 22: row 23: row 24: row 25: row 26: row 27: ekpunk row 28: row 29: row 30: ndig row 31: row 34:",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "headed headed <Recommend-1: Organizational treatment phase> (from previous page)",
      "text": "Directive Directive 2001/ 83/ the the benefit/ risk",
      "start_page": 155,
      "end_page": 155
    }
  ]
}